1. Home
  2. AMRC vs NUVB Comparison

AMRC vs NUVB Comparison

Compare AMRC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ameresco Inc.

AMRC

Ameresco Inc.

HOLD

Current Price

$26.37

Market Cap

1.4B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.28

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMRC
NUVB
Founded
2000
2018
Country
United States
United States
Employees
N/A
291
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
AMRC
NUVB
Price
$26.37
$4.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
8
Target Price
$37.88
$11.38
AVG Volume (30 Days)
418.0K
4.5M
Earning Date
03-02-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.49
N/A
Revenue
$1,769,928,000.00
N/A
Revenue This Year
$10.66
$182.76
Revenue Next Year
$8.93
$91.83
P/E Ratio
$54.77
N/A
Revenue Growth
28.76
N/A
52 Week Low
$8.49
$1.57
52 Week High
$44.93
$9.75

Technical Indicators

Market Signals
Indicator
AMRC
NUVB
Relative Strength Index (RSI) 41.58 34.35
Support Level $26.29 $4.04
Resistance Level $31.12 $5.73
Average True Range (ATR) 1.60 0.28
MACD 0.03 -0.01
Stochastic Oscillator 30.56 25.92

Price Performance

Historical Comparison
AMRC
NUVB

About AMRC Ameresco Inc.

Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: